NANOLEK received a registration certificate from the Ministry of Health of the Republic of Belarus for the POLIMILEX medicine - an inactivated vaccine to prevent poliomyelitis. The corresponding certificate No. 10881/20 was issued on December 15, 2020, for five years.

Vaccination is one of the priority directions of NANOLEK’s activity, constituting more than 40% of the total portfolio.

In Russia, NANOLEK, together with the Dutch company Bilthoven Biologicals, launched a project for the phased transfer of the technology for the production of POLIMILEX - an inactivated vaccine for the prevention of poliomyelitis in 2012. Meanwhile, in 2017, the full-cycle production began (all stages, including quality control) at the NANOLEK production facilities in the Kirov Region. To date, production volumes fully cover the current needs of the Russian market. In the period from 2017 to 2020, as many as 10 million doses of vaccine were supplied for the National Vaccination Schedule of the Russian Federation. The full cycle production of the POLIMILEX vaccine has already proven its safety and high efficiency: the NANOLEK biopharmaceutical complex in the Kirov Region has international quality management certificates. It manufactures products under GMP standards. The production facilities make it possible to supply this vaccine for exportation.

Vladimir Khristenko, President of NANOLEK:

“There is currently a shortage of inactivated polio vaccines on the international market. Being a socially responsible company, NANOLEK supports the global polio eradication program implemented by the WHO, with the planned transition to the use of inactivated vaccines instead of living ones. The Republic of Belarus is also concerned about this problem. According to experts of the Republic of Belarus, about 300 thousand doses of polio vaccine will be required”.

Earlier, NANOLEK received a registration certificate from the Ministry of Health of the Republic of Belarus for the socially significant medicine Hunterase (Idursulfase beta) to treat a rare orphan disease type II Mucopolysaccharidosis and made the first shipments. The medication is produced jointly with Green Cross (Republic of Korea).